Evidence map›Paper›PMID 39695714›Full record

ArticleHealth research policy and systems2024

Health equity innovation in precision medicine: data stewardship and agency to expand representation in clinicogenomics.

Patrick J Silva, Vasiliki Rahimzadeh, Reid Powell, Junaid Husain, Scott Grossman, Adam Hansen, Jennifer Hinkel, Rafael Rosengarten, Marcia G Ory, Kenneth S Ramos

Abstract read
In one paragraph

Article in Health research policy and systems, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Patrick J SilvaTexas A&M Health, School of Medicine, Health Professions Education Building 8447 Riverside Pkwy, Bryan, TX, 77807, United States of America. ricksilva@tamu.edu.
Vasiliki RahimzadehBaylor College of Medicine, 1 Baylor Plz, Houston, TX, 77030, United States of America.
Reid PowellTexas A&M Health, School of Medicine, Health Professions Education Building 8447 Riverside Pkwy, Bryan, TX, 77807, United States of America.
Junaid HusainGreater Houston Healthconnect, 1200 Binz St Suite 1495, Houston, TX, 77004, United States of America.
Scott GrossmanMerck and Co., 126 East Lincoln Avenue, Rahway, NJ, 07065, United States of America.
Adam HansenGeneial, Houston, TX, United States of America.
Jennifer HinkelThe Data Economics Company, Los Angeles, CA, 90064, United States of America.
Rafael RosengartenGenialis, 2726 Bissonnet St Suite 240-374, Houston, TX, 77005, United States of America.
Marcia G OryDepartment of Environmental and Occupational Health, Center for Population Health and Aging, Texas A&M University School of Public Health, 212 Adriance Lab Rd, College Station, TX, 77843, United States of America.
Kenneth S RamosTexas A&M Health, School of Medicine, Health Professions Education Building 8447 Riverside Pkwy, Bryan, TX, 77807, United States of America. Kramos@tamu.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Most forms of clinical research examine a very minute cross section of the patient journey. Much of the knowledge and evidence base driving current genomic medicine practice entails blind spots arising from underrepresentation and lack of research participation in clinicogenomic databases. The flaws are perpetuated in AI models and clinical practice guidelines that reflect the lack of diversity in data being used. Participation in clinical research and biobanks is impeded in many populations due to a variety of factors that include knowledge, trust, healthcare access, administrative barriers, and technology gaps. A recent symposium brought industry, clinical, and research participants in clinicogenomics to discuss practical challenges and potential for new data sharing models that are patient centric and federated in nature and can address health disparities that might be perpetuated by lack of diversity in clinicogenomic research, biobanks, and datasets. Clinical data governance was recognized as a multiagent problem, and governance practices need to be more patient centric to address most barriers. Digital tools that preserve privacy, document provenance, and enable the management of data as intellectual property have great promise. Policy updates realigning and rationalizing clinical data governance practices are warranted.

Indexed as

GenomicsHealth EquityPrecision MedicineBiological Specimen BanksBiomedical ResearchHumansInformation DisseminationIntellectual PropertyClinicogenomic registriesData infrastructureHealth equityInteroperabilityPrecision medicine

Identifiers

PMID39695714
PMCPMC11657299

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.